HexAbs used in the study
| Designation . | CH3-AD2-IgG module . | CH1-DDD2-Fab module . | |||
|---|---|---|---|---|---|
| Current . | Previous . | Ab . | Ag . | Ab . | Ag . |
| 20-(74)-(74) | NA | Veltuzumab | CD20 | Milatuzumab | CD74 |
| 74-(20)-(20) | NA | Milatuzumab | CD74 | Veltuzumab | CD20 |
| 74-(74)-(74) | NA | Milatuzumab | CD74 | Milatuzumab | CD74 |
| 20-(20)-(20) | 20-20 | Veltuzumab | CD20 | Veltuzumab | CD20 |
| 20-(22)-(22) | 20-22 | Veltuzumab | CD20 | Epratuzumab | CD22 |
| 22-(20)-(20) | 22-20 | Epratuzumab | CD22 | Veltuzumab | CD20 |
| Designation . | CH3-AD2-IgG module . | CH1-DDD2-Fab module . | |||
|---|---|---|---|---|---|
| Current . | Previous . | Ab . | Ag . | Ab . | Ag . |
| 20-(74)-(74) | NA | Veltuzumab | CD20 | Milatuzumab | CD74 |
| 74-(20)-(20) | NA | Milatuzumab | CD74 | Veltuzumab | CD20 |
| 74-(74)-(74) | NA | Milatuzumab | CD74 | Milatuzumab | CD74 |
| 20-(20)-(20) | 20-20 | Veltuzumab | CD20 | Veltuzumab | CD20 |
| 20-(22)-(22) | 20-22 | Veltuzumab | CD20 | Epratuzumab | CD22 |
| 22-(20)-(20) | 22-20 | Epratuzumab | CD22 | Veltuzumab | CD20 |